Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO MomentumIts trading | Count Crypto | investorshub | 09/27/2023 7:05:39 AM |
$OKYO MomentumIts now last up | Pisd | investorshub | 09/27/2023 1:43:07 AM |
$OKYO great article | Pisd | investorshub | 09/27/2023 1:42:23 AM |
Good read | mfayman | investorshub | 09/27/2023 1:10:35 AM |
$OKYO Price gaining | mfayman | investorshub | 09/26/2023 10:25:03 PM |
got some short data | mfayman | investorshub | 09/26/2023 9:58:21 PM |
short data if anyone is interested | Ryguy008 | investorshub | 09/26/2023 6:24:49 PM |
$OKYO MomentumIts now up | glenn1919 | investorshub | 09/26/2023 6:22:08 PM |
The gaining last trade up | mfayman | investorshub | 09/26/2023 5:24:24 PM |
$OKYO and the shorts continue | Boris the Spider | investorshub | 09/26/2023 5:13:44 PM |
$OKYO MomentumIts trading | mfayman | investorshub | 09/26/2023 2:34:45 PM |
$OKYO What do you make of this? | Boris the Spider | investorshub | 09/26/2023 1:01:34 PM |
$OKYO MomentumIts gaining | mfayman | investorshub | 09/26/2023 12:46:16 PM |
$OKYO MomentumIts trading | Anita Dump | investorshub | 09/26/2023 12:41:02 PM |
The trading up | mfayman | investorshub | 09/26/2023 10:39:04 AM |
$OKYO The gaining last up | mfayman | investorshub | 09/26/2023 10:34:44 AM |
$OKYO Good read | Ryguy008 | investorshub | 09/26/2023 10:08:10 AM |
$OKYO MomentumIts gaining up | mfayman | investorshub | 09/26/2023 9:18:55 AM |
$OKYO When is this gonna take off? | Count Crypto | investorshub | 09/26/2023 8:46:01 AM |
The trading up | glenn1919 | investorshub | 09/26/2023 8:39:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...